Syros Announces Appointment of Conley Chee as Chief Commercial Officer
September 27 2021 - 8:00AM
Business Wire
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development
of medicines that control the expression of genes, today announced
the appointment of Conley Chee as the company’s first Chief
Commercial Officer. Mr. Chee brings 20 years of pharmaceutical
sales leadership, marketing and strategy experience in the U.S. and
globally, with particular expertise in driving commercial strategy
for novel medicines for the treatment of cancer.
“We are pleased to welcome Conley to Syros. With multiple
programs progressing through late-stage development and towards
potential new drug applications in 2024, now is the right time to
begin building our commercial organization,” said Nancy Simonian,
M.D., Chief Executive Officer of Syros. “Conley brings a wealth of
relevant experience in oncology commercial leadership, including a
track record of building effective commercial organizations and
successfully launching new targeted therapies. We look forward to
his many contributions as we mature Syros into a fully integrated
biopharmaceutical company and work to deliver our medicines to
patients in need.”
Mr. Chee joins Syros from Novartis Pharmaceuticals, where he
most recently served as Global Head of Portfolio Management, Global
Pipeline Strategy and Precision Medicine. In this role, Mr. Chee
had strategic responsibility for shaping Novartis’ overall
pipeline, including driving commercial planning for the company’s
early-stage portfolio and diagnostics strategy for oncology.
Earlier in his career at Novartis, Mr. Chee served as Vice
President – Global Head Oncology Lung Franchise, as well as
multiple US sales and marketing leadership roles. Prior to joining
Novartis, Mr. Chee spent five years in roles of increasing
responsibility at Pfizer, ultimately serving as Team Leader of
International Business Development. He holds an M.B.A from the
Richard Ivey School of Business at the University of Western
Ontario and B.Sc. Pharm from the University of Alberta, and
completed his residency in Clinical Pharmacy at the University of
British Columbia.
“Syros’ growing portfolio of later-stage targeted
investigational medicines has the potential to offer new standards
of care to people with hematologic malignancies who need and
deserve better treatment options,” said Mr. Chee. “I look forward
to working with the leadership team to develop a commercial
strategy that maximizes synergies across Syros’ portfolio to bring
products to market and profoundly impact the lives of
patients.”
About Syros Pharmaceuticals
Syros is redefining the power of small molecules to control the
expression of genes. Based on its unique ability to elucidate
regulatory regions of the genome, Syros aims to develop medicines
that provide a profound benefit for patients with diseases that
have eluded other genomics-based approaches. Syros is advancing a
robust clinical-stage pipeline, including: tamibarotene, a
first-in-class oral selective RARα agonist in RARA-positive
patients with higher-risk myelodysplastic syndrome and acute
myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide in
patients with acute promyelocytic leukemia; and SY-5609, a highly
selective and potent oral CDK7 inhibitor in patients with select
solid tumors and blood cancers. Syros also has multiple preclinical
and discovery programs in oncology and monogenic diseases.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of The Private Securities Litigation Reform Act of
1995, including without limitation statements regarding the
expected timing of filing of new drug applications, the ability to
commercialize products, and the therapeutic application and
potential of Syros’s programs, including the ability to offer new
standards of care to people with hematologic malignancies. The
words ‘‘anticipate,’’ ‘‘believe,’’ ‘‘continue,’’ ‘‘could,’’
‘‘estimate,’’ ‘‘expect,’’ “hope,” ‘‘intend,’’ ‘‘may,’’ ‘‘plan,’’
‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘target,’’ ‘‘should,’’
‘‘would,’’ and similar expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. Actual results or
events could differ materially from the plans, intentions and
expectations disclosed in these forward-looking statements as a
result of various important factors, including Syros’ ability to:
advance the development of its programs, including its targeted
hematology and CDK7 programs, under the timelines it projects in
current and future clinical trials; demonstrate in any current and
future clinical trials the requisite safety, efficacy and
combinability of its drug candidates; replicate scientific and
non-clinical data in clinical trials; successfully develop a
companion diagnostic test to identify patients with the RARA
biomarker; obtain and maintain patent protection for its drug
candidates and the freedom to operate under third party
intellectual property; obtain and maintain necessary regulatory
approvals; identify, enter into and maintain collaboration
agreements with third parties, including its ability to perform
under its collaboration agreements with Incyte Corporation and
Global Blood Therapeutics; manage competition; manage expenses;
raise the substantial additional capital needed to achieve its
business objectives; attract and retain qualified personnel; and
successfully execute on its business strategies; risks described
under the caption “Risk Factors” in Syros’ Annual Report on Form
10-K for the year ended December 31, 2020 and Quarterly Report on
Form 10-Q for the quarter ended June 30, 2021, each of which is on
file with the Securities and Exchange Commission; and risks
described in other filings that Syros makes with the Securities and
Exchange Commission in the future. In addition, the extent to which
the COVID-19 outbreak continues to impact our workforce and our
discovery research, supply chain and clinical trial operations
activities, and the operations of the third parties on which we
rely, will depend on future developments, which are highly
uncertain and cannot be predicted with confidence, including the
duration and severity of the outbreak, additional or modified
government actions, and the actions that may be required to contain
the virus or treat its impact. Any forward-looking statements
contained in this press release speak only as of the date hereof,
and Syros expressly disclaims any obligation to update any
forward-looking statements, whether because of new information,
future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210927005178/en/
Media Contact Courtney Solberg Syros Pharmaceuticals
917-698-9253 csolberg@syros.com Investor Contact Hannah
Deresiewicz Stern Investor Relations, Inc. 212-362-1200
hannah.deresiewicz@sternir.com
Syros Pharmaceuticals (NASDAQ:SYRS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Syros Pharmaceuticals (NASDAQ:SYRS)
Historical Stock Chart
From Apr 2023 to Apr 2024